GLMD - Galmed Pharmaceuticals Ltd.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
9.00
-0.04 (-0.44%)
At close: 4:00PM EST

9.00 0.00 (0.00%)
After hours: 4:20PM EST

Stock chart is not supported by your current browser
Previous Close9.04
Open9.03
Bid6.40 x 200
Ask9.36 x 100
Day's Range8.96 - 9.29
52 Week Range3.13 - 9.78
Volume71,683
Avg. Volume49,717
Market Cap114.602M
Beta2.98
PE Ratio (TTM)N/A
EPS (TTM)-1.22
Earnings DateNov 6, 2017 - Nov 10, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.40
Trade prices are not sourced from all markets
  • Galmed Pharmaceuticals Ltd. :GLMD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
    Capital Cube16 days ago

    Galmed Pharmaceuticals Ltd. :GLMD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017

    Categories: Yahoo FinanceGet free summary analysis Galmed Pharmaceuticals Ltd. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Galmed Pharmaceuticals Ltd. – Foamix Pharmaceuticals Ltd., EyeGate Pharmaceuticals, Inc. and Aerie Pharmaceuticals, Inc. (FOMX-US, EYEG-US and AERI-US) that have also reported for this period. Highlights Summary numbers: ... Read more (Read more...)

  • PR Newswire18 days ago

    Galmed Pharmaceuticals to Present at HEP DART 2017 Meeting

    TEL AVIV, Israel, Nov. 27, 2017 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and other liver diseases, today announced that Dr. Carol L. Brosgart, Clinical Professor of Medicine, Epidemiology and Biostatistics, University of California, San Francisco (UCSF), a member of Galmed's board of directors, will present at the 22nd biennial HEP DART meeting, to be held at Kona, Hawaii, December 3-7, 2017.

  • Should You Buy Galmed Pharmaceuticals Ltd (GLMD) At $8.03?
    Simply Wall St.21 days ago

    Should You Buy Galmed Pharmaceuticals Ltd (GLMD) At $8.03?

    Galmed Pharmaceuticals Ltd (NASDAQ:GLMD), a biotechnology company based in Israel, saw a double-digit share price rise of over 10% in the past couple of months on the NasdaqCM. As aRead More...

  • Associated Presslast month

    Galmed Pharmaceuticals reports 3Q loss

    On a per-share basis, the Tel Aviv, Israel-based company said it had a loss of 23 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • PR Newswirelast month

    Galmed Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update

    - Conference Call and Webcast Today at 8:30 a.m. EST / 5:30 a.m. PST - TEL AVIV, Israel , Nov. 9, 2017 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), ...

  • ACCESSWIRElast month

    Galmed Pharmaceuticals Ltd. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 9, 2017 / Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 9, 2017 at 8:30 AM ...

  • PR Newswirelast month

    Galmed Pharmaceuticals to Provide Corporate Overview at the Stifel 2017 Healthcare Conference

    TEL AVIV, Israel , Nov. 07, 2017 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the ...

  • PR Newswirelast month

    Galmed Pharmaceuticals to Report Third Quarter Financial Results on Thursday, November 9th

    TEL AVIV, Israel, Nov. 1, 2017 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and other liver diseases, today announced that it will host a conference call and webcast to discuss results for the three and nine months ended September 30, 2017 and to provide an update on current developments with respect to its clinical programs for Aramchol™ on Thursday, November 9, 2017. Aramchol™ (arachidyl amido cholanoic acid) is a novel fatty acid bile acid conjugate, inducing beneficial modulation of intra-hepatic lipid metabolism. Aramchol™'s ability to modulate hepatic lipid metabolism was discovered and validated in animal models, demonstrating downregulation of the three key pathologies of NASH: steatosis, inflammation and fibrosis.

  • PR Newswire2 months ago

    Galmed Pharmaceuticals to Host Key Opinion Leader Meeting on Non-Alcoholic Steato-Hepatitis (NASH)

    TEL AVIV, Israel, Oct. 19, 2017 /PRNewswire/ -- Galmed Pharmaceuticals, Inc. (GLMD), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and other liver diseases, today announced that it will host a Key Opinion Leader (KOL) meeting on NASH on Thursday, October 26, 2017 in New York City. The meeting will feature a presentation by KOL Professor Scott Friedman, MD (Icahn School of Medicine at Mount Sinai), who will discuss the current treatment landscape and unmet medical need for patients with NASH.  Professor Friedman will be available to answer questions at the conclusion of the event.

  • PR Newswire2 months ago

    Galmed Pharmaceuticals Announces Publication of Data on Aramchol™ Mechanism of Action in Hepatology Communications. Data Will Also Be Presented at AASLD

    TEL AVIV, Israel, Oct. 5, 2017 /PRNewswire/ -- Galmed Pharmaceuticals, Inc. (GLMD), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and other liver diseases, today announced the publication of a paper entitled "Role of Aramchol™ in steatohepatitis and fibrosis in mice" in Hepatology Communications, a peer-reviewed, online open access journal. The paper summarizes the work conducted by a collaboration of key international, basic and clinical scientists, who are well known NASH experts. "The paper reinforced the previously published effects of Aramchol on steatosis in patients,ˮ said Dr. Liat Hayardeny, Chief Scientific Officer of Galmed.

  • 3 Reasons Why Galmed Pharmaceuticals (GLMD) is a Great Momentum Stock
    Zacks3 months ago

    3 Reasons Why Galmed Pharmaceuticals (GLMD) is a Great Momentum Stock

    Momentum stock investors will love Galmed Pharmaceuticals (GLMD) as it has favorable price performance and is also seeing positive estimate revisions.

  • PR Newswire4 months ago

    Galmed Pharmaceuticals Announces Pricing of Offering of Ordinary Shares to Existing Investors and Members of the Board of Directors

    The closing of the registered direct offering is expected to take place on or about August 9, 2017, subject to the satisfaction of customary closing conditions, and the closing of the private placement is expected to take place no later than September 15, 2017, subject to the satisfaction of customary closing conditions. The ordinary shares to be issued in the registered direct offering described above are being offered pursuant to a shelf registration statement on Form F-3 (File No. 333-203133) which was declared effective by the Securities and Exchange Commission ("SEC") on June 1, 2015.  A prospectus supplement and accompanying base prospectus relating to the registered direct offering will be filed with the SEC. When available, copies of the prospectus supplement and the accompanying base prospectus relating to this offering may be obtained at the SEC's website at http://www.sec.gov or by contacting the Company at Attn: Investor Relations, 16 Tiomkin St., Tel Aviv 6578317, Israel or by telephone at + (972) 3 693 8448.

  • Associated Press5 months ago

    Galmed Pharmaceuticals reports 2Q loss

    On a per-share basis, the Tel Aviv, Israel-based company said it had a loss of 22 cents. The biopharmaceutical company posted revenue of $270,000 in the period. Galmed Pharmaceuticals shares have more ...

  • PR Newswire5 months ago

    Galmed Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update

    - Conference Call and Webcast Today at 8:30 a.m. EDT / 5:30 a.m. PDT - TEL AVIV, Israel , July 31, 2017 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), ...

  • Galmed Pharmaceuticals (GLMD) Catches Eye: Stock Gains 15.7%
    Zacks5 months ago

    Galmed Pharmaceuticals (GLMD) Catches Eye: Stock Gains 15.7%

    Galmed Pharmaceuticals Ltd. (GLMD) shares jumped nearly 16% in the last trading session.

  • PR Newswire5 months ago

    Galmed Pharmaceuticals Second Quarter 2017 Conference Call and Webcast Scheduled for Monday, July 31, 2017

    TEL AVIV, Israel, July 24, 2017 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, and other liver diseases, announced today that it will host a conference call and webcast on Monday, July 31, 2017, to discuss results for the period ended June 30, 2017 and to provide an update on current developments with respect to its clinical programs for Aramchol™. Aramchol™ (arachidyl amido cholanoic acid) is a novel fatty acid bile acid conjugate, inducing beneficial modulation of intra-hepatic lipid metabolism.

  • PR Newswire6 months ago

    Galmed Pharmaceuticals Announces the Election of Dr. Carol L. Brosgart as a New Member of the Board of Directors

    TEL AVIV, Israel, June 8, 2017 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, and other liver diseases, announced today that on June 7, 2017, the Company held an annual general meeting of shareholders (the "Meeting"), at which the Company's shareholders voted to elect Dr. Carol L. Brosgart as a new Class I director to serve as a member of the board of directors until the close of the annual general meeting to be held in 2018. Dr. Brosgart brings a vast array of clinical, policy and corporate experience to Galmed having held senior management positions with several leading pharmaceutical and life sciences companies.

  • Associated Press7 months ago

    Galmed Pharmaceuticals reports 1Q loss

    The Tel Aviv, Israel-based company said it had a loss of 26 cents per share. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was ...

  • PR Newswire7 months ago

    Galmed Pharmaceuticals Reports First Quarter 2017 Financial Results

    TEL AVIV, Israel, May 15, 2017 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development ...

  • PR Newswire7 months ago

    Galmed Pharmaceuticals First Quarter 2017 Conference Call and Webcast Scheduled for Monday, May 15th, 2017

    TEL AVIV, Israel, May 8, 2017 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development ...

  • PR Newswire8 months ago

    Galmed Pharmaceuticals to Present at International Liver Congress Data that Shows Aramchol™ has a Potential Direct Effect on Liver Fibrosis

    TEL AVIV, Israel, April 5, 2017 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development ...

  • Associated Press9 months ago

    Galmed Pharmaceuticals reports 4Q loss

    On a per-share basis, the Tel Aviv, Israel-based company said it had a loss of 40 cents. The biopharmaceutical company posted revenue of $274,000 in the period, which topped Street forecasts. Three analysts ...

  • PR Newswire9 months ago

    Galmed Pharmaceuticals Fourth Quarter 2016 Conference Call and Webcast Scheduled for Thursday, March 23rd, 2017

    TEL AVIV, Israel, March 16, 2017 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, and other liver diseases, announced today that it will host a conference call and webcast on Thursday, March 23rd, 2017, to provide an update on its clinical programs and its new insights into the mechanism of actions of Aramchol as well as to discuss financial results for the period ended December 31, 2016. Aramchol™ (arachidyl amido cholanoic acid) is a novel fatty acid bile acid conjugate, inducing beneficial modulation of intra-hepatic lipid metabolism.

  • PR Newswire11 months ago

    Galmed Pharmaceuticals Completes Patient Recruitment for ARREST Phase IIb NASH study

    TEL AVIV, Israel,, Jan 9, 2017 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a once-daily, oral therapy for the treatment of liver diseases including Non-Alcoholic Steato-Hepatitis (NASH), announced today that it has completed recruitment for its Phase IIb ARREST study ("ARREST Study"). The ARREST Study is a global, multi-center, randomized, double blind, placebo-controlled, Phase IIb clinical trial evaluating the treatment effects and safety of Aramchol in 240 patients with biopsy proven NASH who are overweight or obese, and who are pre-diabetic or type-II-diabetic. The ARREST Study primary endpoint, previously demonstrated in a Phase IIa study, is reduction in liver fat content measured by magnetic resonance spectroscopy (MRS).  The secondary histological endpoints include improvement of fibrosis, two-point improvement in NAS (NAFLD Activity Score) and resolution of NASH.